ArticleStem cell research & therapy2015
Comparison of biological characteristics of mesenchymal stem cells derived from maternal-origin placenta and Wharton's jelly.
Article in Stem cell research & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Systematic review of patient factors affecting adipose stem cell viability and function: implications for regenerative therapy.Stem cell research & therapy · 2017Pooled it
- Comparative Study of Mesenchymal Stem Cell Identity and Chondrogenic Differentiation Capacity of Human Nucleus Pulposus, Adipose and Bone Marrow Tissues Derived Mesenchymal Stem Cells.Tissue engineering and regenerative medicine · 2026Article
- Placental Mesenchymal Stem Cell-Derived Extracellular Vesicles (PMSC-EVs) as an Innovative Therapy for Diabetic Wound Healing.International journal of molecular sciences · 2026Review
- Role of Mesenchymal Stem/Stromal Cells (MSCs) and MSC-Derived Extracellular Vesicles (EVs) in Prevention of Telomere Length Shortening, Cellular Senescence, and Accelerated Biological Aging.Bioengineering (Basel, Switzerland) · 2024Review
- Human umbilical cord/placenta mesenchymal stem cell conditioned medium attenuates intestinal fibrosis in vivo and in vitro.Stem cell research & therapy · 2024Article
- The heterogeneity of mesenchymal stem cells: an important issue to be addressed in cell therapy.Stem cell research & therapy · 2023Review
- Article
- Stem cell sources from human biological waste material: a role for the umbilical cord and dental pulp stem cells for regenerative medicine.Human cell · 2023Review
- Article
- Biological characteristics of stem cells derived from burned skin-a comparative study with umbilical cord stem cells.Stem cell research & therapy · 2021Article
- Therapeutic Potential of HUMSCs in Female Reproductive Aging.Frontiers in cell and developmental biology · 2021Review
- Review
- Perinatal Derivatives: Where Do We Stand? A Roadmap of the Human Placenta and Consensus for Tissue and Cell Nomenclature.Frontiers in bioengineering and biotechnology · 2020Review
- The Higher Inherent Therapeutic Potential of Biomaterial-Based hDPSCs and hEnSCs for Pancreas Diseases.Frontiers in bioengineering and biotechnology · 2020Article
- Aldehyde dehydrogenase activity of Wharton jelly mesenchymal stromal cells: isolation and characterization.Cytotechnology · 2019Article
- Role of Toll-Like Receptors in Actuating Stem/Progenitor Cell Repair Mechanisms: Different Functions in Different Cells.Stem cells international · 2019Review
- Comparative evaluation of mesenchymal stromal cells from umbilical cord and amniotic membrane in xeno-free conditions.BMC cell biology · 2018Article
- Neuroprotective Potential and Paracrine Activity of Stromal Vs. Culture-Expanded hMSC Derived from Wharton Jelly under Co-Cultured with Hippocampal Organotypic Slices.Molecular neurobiology · 2018Article
- Comparison of the Biological Characteristics of Mesenchymal Stem Cells Derived from the Human Placenta and Umbilical Cord.Scientific reports · 2018Article
- Placenta-Derived Adherent Stromal Cell Therapy for Hematopoietic Disorders: A Case Study of PLX-R18.Cell transplantation · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlthough mesenchymal stem cells (MSCs) from different sources share many similar characteristics, they also exhibit individual properties. In this study, we compared MSCs derived from Wharton's jelly in the umbilical cord with those derived from the decidual basalis in the maternal part of the placenta to better understand the similarities and differences between these two cell types.
methodThe morphology, immunophenotype (as assessed using flow cytometry), and multi-lineage differentiation potential were analyzed. Karyotype analysis was carried out to determine the origin of the MSCs. Growth kinetics were evaluated using analysis of the population doubling time and cell cycle. Immunosuppressive function was analyzed using mixed lymphocyte culture.
resultsMSCs from Wharton's jelly and the decidua basalis exhibited similar morphology, immunophenotype, and differentiation potential to osteogenesis and adipogenesis. The percentage of MSCs in the G0/G1 phase was higher in the case of Wharton's jelly than in the case of the decidua basalis (P < 0.05). Decidual MSCs displayed more remarkable immunosuppressive effects on phytohemagglutinin-stimulated T-cell proliferation (P < 0.05).
conclusionMSCs from both sources had similar basic biological properties, but decidual MSCs had slower proliferation and stronger immunosuppressive function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.